A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers

Launched by GENENTECH, INC. · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients must have the following:
• • Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals.
• • The ability to understand and sign a written informed consent form, which must be obtained prior to study entry.
• • Be available for 24 weeks so that follow up may be completed.
• • Qualify for care as Department of Defense health care beneficiary.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• • Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results.
• Concurrent Medication:
• Excluded:
• • Corticosteroids or other known immunosuppressive drugs.
• • Any experimental agents.
• Patients with the following are excluded:
• • Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results.
• Prior Medication:
• Excluded within 30 days of study entry:
• • Zidovudine or other anti-retroviral agents.